- Home
- VRCA vs SACH Comparison
VRCA vs SACH Comparison
Compare VRCA & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | SACH |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 52.0M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VRCA | SACH |
|---|---|---|
| Price | $8.28 | $1.12 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 378.4K | 181.0K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 18.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | $3,906,000.00 |
| Revenue This Year | $373.65 | N/A |
| Revenue Next Year | N/A | $1.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | N/A |
| 52 Week Low | $3.28 | $0.80 |
| 52 Week High | $12.00 | $1.48 |
Technical Indicators
Market Signals| Indicator | VRCA | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 65.85 | 62.46 |
| Support Level | $6.26 | $1.00 |
| Resistance Level | $9.78 | $1.14 |
| Average True Range (ATR) | 1.12 | 0.05 |
| MACD | 0.36 | 0.01 |
| Stochastic Oscillator | 72.96 | 88.89 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.